BioCentury | Oct 7, 2020
Finance

With life sciences now a ‘core’ investment area, General Atlantic picks a global head

...a 2007 investment in WuXi PharmaTech Inc.More recently, it has funded biotechs including Immunocore Ltd., Canbridge Pharmaceuticals Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...to ignore,” said Stone, who is the firm’s chief investment officer.Zai Lab Ltd. (NASDAQ:ZLAB), Everest Medicines Ltd. and Canbridge...
...Everest, which was incubated by C-Bridge Capital, has a pipeline spanning a range of disease areas; and Canbridge...
...focuses on targeted cancer therapies and orphan disease programs (see “Zai: Capitalizing on China”; “Incubating in China”;  “Canbridge...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Dinsmore as CSO. He was a Third Rock entrepreneur-in-residence. Beijing-based cancer and rare disease company Canbridge Pharmaceuticals Inc....
...NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst BioMedica Kronos Bio Inc. Canbridge Pharmaceuticals Inc. Healx...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

...active antibody-mediated rejection. Financial terms were not disclosed. Canbridge, UMass collaborate on neuromuscular gene therapies Canbridge Pharmaceuticals Inc....
...of Illinois in Chicago. Targets IL-6 - Interleukin-6 BioCentury Staff Eli Lilly and Co. Evox Therapeutics Ltd. CSL Vitaeris Inc. Sanofi Alphamab Oncology Canbridge Pharmaceuticals Inc. University...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...low double digits based on annual net sales. China approves Canbridge’s NDA for Puma’s Nerlynx Canbridge Pharmaceuticals Inc....
...as an extended adjuvant treatment for early stage, HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. Canbridge...
...Sodium-glucose cotransporter 2 BioCentury Staff Nerlynx (Brand), PB272 (Compound #), HKI-272 (Compound #), Oral neratinib (Generic) Puma Biotechnology Inc. Canbridge Pharmaceuticals Inc. Tetraphase...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

...hired David Cook as SVP and CSO. He was CSO of Seres Therapeutics Inc. (NASDAQ:MCRB). Canbridge Pharmaceuticals Inc....
...a February series D to prepare for two expected NDA approvals in mainland China (see “Canbridge...
...NextCode Genomics Inc. Robin Sawka, BioCentury Staff Radius Health Inc. Anika Therapeutics Inc. AMAG Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc. Forma Therapeutics Inc. Canbridge Pharmaceuticals Inc. 6...
BioCentury | Apr 9, 2020
Finance

Qiming readies to deploy $1.1B new China fund in the age of COVID-19

...due to the pandemic, Qiming’s portfolio companies have continued to close on investments. Most recently, Canbridge Pharmaceuticals Inc....
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge...
...Capital and YuanMing Prudence Fund and existing investor Tigermed. Chairman and CEO James Xue said Canbridge Pharmaceuticals Inc.'s...
..."gateway or one-stop shop" partner for ex-China companies seeking access to the Chinese market (see "Canbridge...
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...it had expected $1.80-$1.90 and $865-$875 million. Hong Kong approves Nerlynx for breast cancer Beijing-based Canbridge Pharmaceuticals Inc....
...an adjuvant therapy for adult patients with early-stage HER2-positive breast cancer previously treated with trastuzumab. Canbridge...
...EP01572, EP-1572, Solorel) University of Texas MD Anderson Cancer Center Myriad Genetics Inc. BioCryst Pharmaceuticals Inc. Torii Pharmaceutical Co. Ltd. Canbridge Pharmaceuticals Inc. Takeda...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...was VP of translational medicine at Kymera Therapeutics Inc. Beijing-based cancer and rare disease company Canbridge Pharmaceuticals Inc....
...Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4 Pharmaceuticals Inc. Nimbus Therapeutics LLC Canbridge Pharmaceuticals Inc. Five...
Items per page:
1 - 10 of 52
BioCentury | Oct 7, 2020
Finance

With life sciences now a ‘core’ investment area, General Atlantic picks a global head

...a 2007 investment in WuXi PharmaTech Inc.More recently, it has funded biotechs including Immunocore Ltd., Canbridge Pharmaceuticals Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...to ignore,” said Stone, who is the firm’s chief investment officer.Zai Lab Ltd. (NASDAQ:ZLAB), Everest Medicines Ltd. and Canbridge...
...Everest, which was incubated by C-Bridge Capital, has a pipeline spanning a range of disease areas; and Canbridge...
...focuses on targeted cancer therapies and orphan disease programs (see “Zai: Capitalizing on China”; “Incubating in China”;  “Canbridge...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Dinsmore as CSO. He was a Third Rock entrepreneur-in-residence. Beijing-based cancer and rare disease company Canbridge Pharmaceuticals Inc....
...NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst BioMedica Kronos Bio Inc. Canbridge Pharmaceuticals Inc. Healx...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

...active antibody-mediated rejection. Financial terms were not disclosed. Canbridge, UMass collaborate on neuromuscular gene therapies Canbridge Pharmaceuticals Inc....
...of Illinois in Chicago. Targets IL-6 - Interleukin-6 BioCentury Staff Eli Lilly and Co. Evox Therapeutics Ltd. CSL Vitaeris Inc. Sanofi Alphamab Oncology Canbridge Pharmaceuticals Inc. University...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...low double digits based on annual net sales. China approves Canbridge’s NDA for Puma’s Nerlynx Canbridge Pharmaceuticals Inc....
...as an extended adjuvant treatment for early stage, HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. Canbridge...
...Sodium-glucose cotransporter 2 BioCentury Staff Nerlynx (Brand), PB272 (Compound #), HKI-272 (Compound #), Oral neratinib (Generic) Puma Biotechnology Inc. Canbridge Pharmaceuticals Inc. Tetraphase...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

...hired David Cook as SVP and CSO. He was CSO of Seres Therapeutics Inc. (NASDAQ:MCRB). Canbridge Pharmaceuticals Inc....
...a February series D to prepare for two expected NDA approvals in mainland China (see “Canbridge...
...NextCode Genomics Inc. Robin Sawka, BioCentury Staff Radius Health Inc. Anika Therapeutics Inc. AMAG Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc. Forma Therapeutics Inc. Canbridge Pharmaceuticals Inc. 6...
BioCentury | Apr 9, 2020
Finance

Qiming readies to deploy $1.1B new China fund in the age of COVID-19

...due to the pandemic, Qiming’s portfolio companies have continued to close on investments. Most recently, Canbridge Pharmaceuticals Inc....
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge...
...Capital and YuanMing Prudence Fund and existing investor Tigermed. Chairman and CEO James Xue said Canbridge Pharmaceuticals Inc.'s...
..."gateway or one-stop shop" partner for ex-China companies seeking access to the Chinese market (see "Canbridge...
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...it had expected $1.80-$1.90 and $865-$875 million. Hong Kong approves Nerlynx for breast cancer Beijing-based Canbridge Pharmaceuticals Inc....
...an adjuvant therapy for adult patients with early-stage HER2-positive breast cancer previously treated with trastuzumab. Canbridge...
...EP01572, EP-1572, Solorel) University of Texas MD Anderson Cancer Center Myriad Genetics Inc. BioCryst Pharmaceuticals Inc. Torii Pharmaceutical Co. Ltd. Canbridge Pharmaceuticals Inc. Takeda...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...was VP of translational medicine at Kymera Therapeutics Inc. Beijing-based cancer and rare disease company Canbridge Pharmaceuticals Inc....
...Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4 Pharmaceuticals Inc. Nimbus Therapeutics LLC Canbridge Pharmaceuticals Inc. Five...
Items per page:
1 - 10 of 52